Akari Therapeutics, Plc announced on December 16, 2024, the appointment of Torsten Hombeck, Ph.D., as its Chief Financial Officer, effective immediately. Dr. Hombeck brings over 20 years of experience in the biotechnology industry, finance, capital markets, and M&A transactions.
Dr. Hombeck previously served as Akari's CFO from 2019 to June 2023, during which time he raised over $50 million for the company. His return is expected to leverage his intimate knowledge of Akari's operations and goals.
Samir Patel, MD, Akari’s Interim President & CEO, stated that Dr. Hombeck's expertise in business and financial acumen, combined with clinical development and commercial experience, is a valuable asset. This appointment is part of the company's ongoing efforts to strengthen its leadership team and advance its ADC platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.